Kostarox 30mg is commonly used to provide supportive relief for adults managing chronic rheumatic diseases, based on its therapeutic profile. The therapeutic areas of use are recognized for conditions such as those described below. It is primarily relevant for patients with conditions like Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis (AS). It is applied when additional symptomatic support is needed to address symptom clusters that create noticeable physiological strain, such as symptoms related to physical discomfort, including pain, joint stiffness, and swelling.

The medication is also commonly used across conditions presenting with acute episodes, and is relevant for easing symptoms that become more disruptive during flare-ups, such as the pronounced pain of Acute Gouty Arthritis flare-ups. It plays a role in managing moderate pain and soreness following procedures like Dental Surgery, and may assist with the discomfort of Primary Dysmenorrhea. This short-term symptomatic assistance contributes to easing the overall symptom load and helps patients cope more steadily with symptom fluctuations when symptoms become more noticeable.

---

Quick Fact: Symptomatic Relief Across Key Domains

The medicine is commonly used for managing symptoms related to inflammatory or irritative states and episodic discomfort. It assists with maintaining functional stability by addressing symptoms that interfere with routine activities.

Eligibility for Kostarox 30mg: Official Regulatory Status

Kostarox 30mg (Etoricoxib) is officially indicated for use only in Adults and Adolescents 16 years of age and older. Use is contraindicated in children under 16 years of age.

Contraindications: Populations Who Must Not Use This Medicine The medicine is absolutely contraindicated for several specific population groups and clinical states, as defined by regulatory documents. These prohibitions include patients with:

• Established heart conditions such as Ischaemic Heart Disease (IHD), Peripheral Arterial Disease (PAD), Cerebrovascular Disease (CVD), or uncontrolled congestive heart failure (NYHA Class II–IV).
• Uncontrolled hypertension (blood pressure persistently above 140/90 mmHg).
• Active gastrointestinal pathology, including peptic ulceration, GI bleeding, or Inflammatory Bowel Disease (IBD).
• Severe organ impairment, specifically severe hepatic dysfunction (Child-Pugh score ge 10) or severe renal impairment (creatinine clearance <30 mL/min).
• A known history of hypersensitivity to Etoricoxib or allergic-type reactions (e.g., asthma, angioedema) after taking aspirin or other NSAIDs.
• Pregnancy and Lactation (breastfeeding).

Restricted or Conditional Use Patients with moderate hepatic dysfunction (Child-Pugh score 7–9) or pre-existing fluid retention are subject to restricted use and require specific caution, as explicitly stated in the regulatory labeling.

Interactions with other medicines and products

Kostarox 30mg (Etoricoxib) has documented interactions with several drug classes and specific medicines, primarily affecting their plasma concentrations or leading to additive pharmacodynamic effects. This information is derived from official regulatory labeling.

Contraindicated Combinations and Key Restrictions

Classification	Interacting Product/Condition	Official Regulatory Statement
Contraindicated	Severe Renal Impairment (Creatinine Clearance < 30 ml/min)	Co-administration is formally contraindicated in this patient population.
Not Recommended	Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	Generally advised against due to an increased risk of gastrointestinal adverse effects.

Officially Documented Pharmacokinetic and Pharmacodynamic Interactions

Kostarox can modify the exposure of co-administered medicines. The regulatory label states that it can increase the plasma levels of Lithium and Ethinyl Estradiol (a component in oral contraceptives), which may necessitate a dosage review of the co-administered drug. Conversely, co-administration with the potent enzyme inducer Rifampicin results in a 65% decrease in Etoricoxib plasma concentration.

Pharmacodynamic effects include an increased risk of bleeding, evidenced by an approximate 13% increase in INR when co-administered with Warfarin. Furthermore, Etoricoxib may diminish the therapeutic effect of Diuretics and certain Antihypertensive agents (ACE Inhibitors and Angiotensin II Antagonists), especially in patients with existing compromised renal function. Monitoring is also required for patients at high risk of Digoxin toxicity.

How Kostarox 30mg Works: Mechanism of Action

Kostarox 30mg (Etoricoxib) functions as a highly selective inhibitor of the enzyme Cyclooxygenase-2 (COX-2). This interaction is central to the drug's pharmacodynamic mechanism, targeting an induced enzyme rather than the constitutive COX-1 isoform.

Binding to the COX-2 active site disrupts the initial step of the arachidonic acid cascade, preventing the conversion of arachidonic acid into prostanoid mediators, specifically prostaglandin E2 (PGE2). This modification of the molecular pathway results in a reduction of PGE2 synthesis at sites of cellular signaling.

Downstream consequences include system-level physiological modulation: a reduction in PGE2 levels both peripherally and centrally reduces the sensitization of nociceptors and lowers the hypothalamic temperature set-point during pyresis. Furthermore, inhibition of COX-2 in non-inflammatory contexts, such as the kidneys and blood vessels, modulates mechanisms that regulate vascular tone and fluid dynamics, thereby altering physiological systems that may influence blood pressure and fluid retention.

How to Use Kostarox 30mg

Kostarox 30 mg (Etoricoxib) is an oral medication with defined administration protocols. The fundamental principle is to utilize the lowest effective daily dose for the shortest possible duration, with the specific regimen determined by the condition being managed.

Administration and Timing

The medicine is delivered as a film-coated tablet intended for oral administration. The tablets are administered once daily (q.d.). The tablets may be taken with or without food; however, administration without food can result in a faster onset of effects.

If a dose is missed, it is recommended to skip the missed dose and resume the normal schedule the following day. A double dose must not be taken to compensate for the missed dose.

Dosing Regimens and Duration Limits

The dose strength varies based on the indication:

Indication	Standard Daily Dose	Maximum Daily Dose	Duration Principle
Osteoarthritis (OA)	30 mg	60 mg	Chronic symptomatic relief
Rheumatoid Arthritis (RA) / Ankylosing Spondylitis (AS)	60 mg	90 mg	Chronic symptomatic relief
Acute Gouty Arthritis	120 mg	120 mg	Maximum 8 days
Postoperative Dental Surgery Pain	90 mg	90 mg	Maximum 3 days

Special Population Instructions

Age Restrictions: The use of Etoricoxib is contraindicated in children and adolescents under the age of 16 years. No dosage adjustment is necessary for older adults.

Hepatic Impairment: For patients with moderate hepatic impairment (Child-Pugh 7–9), the dose must not exceed 30 mg once daily for any condition. For mild hepatic impairment (Child-Pugh 5–6), the dose must not exceed 60 mg once daily.

This overview summarizes the official research studies and findings that governmental and scientific bodies rely on to understand the use of Etoricoxib, the active ingredient in Kostarox 30mg. This information describes patterns observed in study populations and does not offer clinical advice or personal predictions.

---

Evidence for Use in Chronic Joint Conditions (Osteoarthritis)

Research for Osteoarthritis (OA) primarily relies on Randomized Controlled Trials (RCTs) focusing on adults experiencing pain and stiffness. These studies were used to explore how symptoms change over time. Researchers monitored how symptoms evolved over defined time intervals, describing patterns related to patient-reported pain scores and functional limitations (e.g., WOMAC index). While long-term observational data exists, there is limited information detailing the patterns observed with the lowest 30mg dose when used for sustained periods.

---

Evidence for Use in Inflammatory Arthritis (RA and AS)

Research examined Etoricoxib in Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS), with studies monitoring disease activity measures like joint counts and overall patient assessments. The evidence level for these conditions is broadly categorized as High in peer-reviewed research summaries. However, pivotal trials for defining primary clinical response predominantly utilized the higher 60mg and 90mg doses, meaning data for the 30mg dose in achieving these specific composite outcomes remains insufficient in large-scale studies.

---

Evidence for Short-Term Symptomatic Relief and Gaps

For acute conditions like Acute Gouty Arthritis flare-ups and pain following Dental Surgery, the evidence consists of very short-term RCTs measuring immediate pain scores. It is important to note that the acute relief phase doses studied (e.g., 90mg or 120mg) are substantially higher than 30mg. The 30mg dose is generally not the primary focus of research for initial acute management. Overall, research provides context but not individual predictions, as subgroup findings are uncertain and results apply primarily to the populations studied.

Key Studies & References

1. Etoricoxib (MedlinePlus Drug Information)

Common questions about Kostarox 30mg (FAQ)

Q: What is Kostarox 30mg used for?

A: Kostarox (etoricoxib) 30mg is indicated for the symptomatic relief of pain and inflammation associated with osteoarthritis.

Q: How does Kostarox work to relieve symptoms?

A: Kostarox belongs to a class of medicines known as selective COX-2 inhibitors. Its mechanism of action is linked to the inhibition of cyclooxygenase-2 (COX-2), which is involved in the production of prostaglandins. Prostaglandins are key mediators of pain and inflammation.

Q: What are the common reported side effects of Kostarox?

A: Common side effects reported in clinical trials may include headache, dizziness, gastrointestinal discomfort such as dyspepsia or abdominal pain, and edema (fluid retention). Patients who experience persistent or severe adverse reactions should consult a healthcare professional.

Q: Is Kostarox taken every day?

A: Kostarox is a prescription medicine, and the frequency and duration of treatment are determined by a healthcare provider based on the specific condition being treated and the individual's response. The dose used for osteoarthritis is typically 30mg once daily.

Q: Can Kostarox be taken with food?

A: Studies indicate that Kostarox may be taken with or without food. Taking it with food may slightly delay the absorption of the drug, but it generally does not affect the overall therapeutic effect. Always follow the specific instructions given by your prescribing physician.

Q: How long does it take for Kostarox to start working?

A: The onset of pain relief action for Kostarox can vary among individuals and conditions. Some individuals may begin to feel relief within 24 hours after starting treatment. Consistent use, as prescribed, is important to achieve the full symptomatic benefit observed in clinical trials.

Q: What should I do if I miss a dose of Kostarox?

A: If a dose is missed, individuals should take it as soon as they remember, unless it is almost time for the next scheduled dose. If it is close to the time for the next dose, the missed dose should be skipped, and the usual dosing schedule should be resumed. Do not take a double dose to make up for a missed one. Specific advice should be sought from a healthcare provider or pharmacist.

Official Storage and Disposal Requirements

The storage and disposal instructions for Kostarox 30mg tablets are based strictly on regulatory documents to ensure product stability and safety.

Storage Conditions

Requirement	Regulatory Specification
Temperature	Does not require any special storage conditions regarding temperature.
Packaging	Must be stored in the original container until use.
Stability	The official shelf life for the product is 36 months (3 years).
Child Safety	Must be kept out of the sight and reach of children.

Disposal Instructions

Official labeling mandates that any unused medicinal product or waste material must be disposed of in accordance with local requirements. There are no specific hazardous waste instructions provided beyond adhering to established local pharmaceutical waste management procedures.